VISTIN PHARMA ASA: årsregnskap 2021 vs 2020
Grew 10% on revenue, slipped into loss, cash halved-plus
approved 2022-04-26; registry 2022-08-17; journal 2022 874197
Summary
What changed
Comparing Årsregnskap 2021 with 2020 for VISTIN PHARMA ASA. Revenue 253.9k NOK → 278.6k NOK (+9.7%). Net result +214.0k NOK → -2 558 NOK. Equity 294.71m NOK → 269.98m NOK.
On the constructive side: revenue rose. Pressures included: operating result weakened; fell into a net loss; equity eroded.
Also worth watching: sharp cash drawdown; paid-in equity reduced; payroll increased. All figures are taken from the published annual accounts for VISTIN PHARMA ASA.
At a glance
Scorecard
What improved
-
↑
Revenue rose
Operating income / revenue moved from 253.9k NOK to 278.6k NOK (+9.7% YoY). Calculated
What deteriorated
-
↓
Operating result weakened
Operating result -2.82m NOK → -4.70m NOK (op. margin -1111.4% → -1686.1%). Calculated
-
↓
Fell into a net loss
Net result flipped from 214.0k NOK profit to a loss of 2 558 NOK. Calculated
-
↓
Equity eroded
Book equity 294.71m NOK → 269.98m NOK (equity ratio 99.7% → 97.2%). Calculated
-
↓
Cash fell
Bank deposits 67.74m NOK → 22.52m NOK (-66.8% YoY). Calculated
Things to notice
-
·
Sharp cash drawdown
Cash fell by more than 60% YoY (67.74m NOK → 22.52m NOK). Check whether funds moved to group receivables, investments, or operating burn. Interpretation
-
·
Paid-in equity reduced
Paid-in equity fell 294.71m NOK → 269.98m NOK — check capital reduction, conversion, or reclassification. Interpretation
-
·
Payroll increased
Salary cost 1.74m NOK → 1.95m NOK (685% → 699% of revenue). Calculated
-
·
COGS moved
COGS / varekostnad 73.29m NOK → 96.10m NOK (+31.1% YoY). Calculated
-
·
Book investments changed
Investment / intangible book value 106.87m NOK → 107.6k NOK. Reported fact